AU2001251612A1 - Roles of jak/stat family members in tolerance induction - Google Patents

Roles of jak/stat family members in tolerance induction

Info

Publication number
AU2001251612A1
AU2001251612A1 AU2001251612A AU5161201A AU2001251612A1 AU 2001251612 A1 AU2001251612 A1 AU 2001251612A1 AU 2001251612 A AU2001251612 A AU 2001251612A AU 5161201 A AU5161201 A AU 5161201A AU 2001251612 A1 AU2001251612 A1 AU 2001251612A1
Authority
AU
Australia
Prior art keywords
jak
roles
family members
tolerance induction
stat family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251612A
Inventor
Wayne William Hancock
Engin Ozkaynak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2001251612A1 publication Critical patent/AU2001251612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AU2001251612A 2000-04-14 2001-04-13 Roles of jak/stat family members in tolerance induction Abandoned AU2001251612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54965400A 2000-04-14 2000-04-14
US09/549,654 2000-04-14
PCT/US2001/012131 WO2001079555A2 (en) 2000-04-14 2001-04-13 Roles of jak/stat family members in tolerance induction

Publications (1)

Publication Number Publication Date
AU2001251612A1 true AU2001251612A1 (en) 2001-10-30

Family

ID=24193892

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251612A Abandoned AU2001251612A1 (en) 2000-04-14 2001-04-13 Roles of jak/stat family members in tolerance induction

Country Status (3)

Country Link
US (1) US6534277B1 (en)
AU (1) AU2001251612A1 (en)
WO (1) WO2001079555A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888324B2 (en) * 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7407943B2 (en) * 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
AU2003207273A1 (en) * 2002-02-27 2003-09-09 Genox Research, Inc. Method of examining allergic disease
US20040101853A1 (en) * 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of STAT2 expression
JP4484708B2 (en) * 2002-09-27 2010-06-16 穣 藤本 Methods for treating autoimmune diseases and methods for screening for therapeutic compounds for autoimmune diseases
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
DK1639014T3 (en) * 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
AU2004252395A1 (en) * 2003-06-30 2005-01-06 Biovitrum Ab (Publ) Methods for identifying agents, which regulate cytokines
JP4664815B2 (en) * 2003-09-11 2011-04-06 ヒュービットジェノミクス株式会社 Method and kit for detecting proliferative disease causing sclerosis, prophylactic and / or therapeutic agent for proliferative disease causing sclerosis, and method and kit for identifying substances effective for prevention and / or treatment of proliferative disease causing sclerosis
US20050287558A1 (en) * 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
US20060003940A1 (en) * 2004-05-11 2006-01-05 Rong-Hwa Lin T-cell death-inducing epitopes
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
FI20041204A0 (en) 2004-09-16 2004-09-16 Riikka Lund Methods for the utilization of new target genes associated with immune-mediated diseases
WO2006044666A2 (en) * 2004-10-15 2006-04-27 Northeastern University Detection of disease associated proteolysis by direct mass spectrometry analysis of low molecular weight peptides
FR2877013A1 (en) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris INDENTIFICATION OF A JAK2 MUTATION INVOLVED IN THE VAQUEZ POLYGLOBULIA
AU2007253909B2 (en) * 2006-05-05 2012-08-09 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCCR
WO2008118883A1 (en) * 2007-03-24 2008-10-02 Isis Pharmaceuticals, Inc. Administering antisense oligonucleotides complementary to human apolipoprotein b
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
DE102009027754A1 (en) * 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Method for inhibiting the maturation of dendritic cells
TWI688395B (en) 2010-03-23 2020-03-21 英翠克頌公司 Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
US10633704B2 (en) 2010-07-23 2020-04-28 Raymond M. Johnson Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant CD8 T-cells
WO2012012797A2 (en) * 2010-07-23 2012-01-26 Indiana University Research And Technology Corporation Methods for isolating and using a subset of cd8 t-cells that are resistant to cyclosporin
AU2017298385A1 (en) * 2016-07-19 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting STAT3
JP6750443B2 (en) * 2016-10-05 2020-09-02 ソニー株式会社 Platelet aggregation analysis method, platelet aggregation analysis device, platelet aggregation analysis program, and platelet aggregation analysis system

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667901B2 (en) 1991-10-25 2008-10-15 Immunex Corporation Novel cytokine
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
AU4535893A (en) * 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
DE69433399T2 (en) 1993-01-22 2004-10-14 Immunex Corp., Seattle DETECTION AND TREATMENT OF MUTATIONS IN A GENE FOR A CD40 LIGAND
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
EP0742721B1 (en) 1993-09-02 1999-05-06 Trustees of Dartmouth College Methods of prolonged suppression of humoral immunity
CN1127351C (en) 1993-09-02 2003-11-12 达特茅斯学院理事 Method for inducing antigen-specific T cell tolerance
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5527884A (en) * 1993-12-21 1996-06-18 President And Fellows Of Harvard College Mediators of chronic allograft rejection and DNA molecules encoding them
AU680102B2 (en) 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5563036A (en) 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
US5583713A (en) * 1994-07-22 1996-12-10 Analog Devices, Inc. Pipelined demodulation and ADC conversion scheme for disk drive servo system
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5821053A (en) * 1995-02-10 1998-10-13 Center For Blood Research, Inc. LIL-Stat DNA binding sites and methods for identifying inhibitory binding agents
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5712094A (en) 1995-03-27 1998-01-27 Ligand Pharmaceuticals, Inc. Methods for detecting modulators of cytokine action
KR100453314B1 (en) 1995-06-07 2004-12-17 임뮤넥스 코포레이션 CD40L Mutein
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997039722A2 (en) * 1996-04-25 1997-10-30 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
DE69738767D1 (en) * 1996-11-01 2008-07-24 Inst Medical W & E Hall THERAPEUTICS AND DIAGNOSTICS THAT REGULATE CELLULAR RESPONSABILITY ON CYTOKINES
CA2277223A1 (en) 1997-01-10 1998-07-16 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US5932425A (en) 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
AU5623398A (en) 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
TR199902817T2 (en) 1997-05-17 2000-09-21 Biogen, Inc. Use of a CD40:CD154 binding interfering agent for inhibition of counter-adaptive bonding reactions, in particular graft rejection .
TR199903141T2 (en) 1997-06-20 2000-09-21 Biogen, Inc. CD154 blockade therapy for therapeutic protein blocker syndrome.
DE69835965T2 (en) 1997-06-20 2007-06-14 Biogen Idec Ma Inc., Cambridge CD154-BLOCKADETHERAPY OF PANCREAS ISOLATED TRANSPLANTATION in primates
AU8266798A (en) 1997-06-27 1999-01-19 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
WO1999045958A1 (en) 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
US6207391B1 (en) * 1998-03-31 2001-03-27 Tularik Inc. High-throughput screening assays for modulators of STAT4 and STAT6 activity

Also Published As

Publication number Publication date
US6534277B1 (en) 2003-03-18
WO2001079555A2 (en) 2001-10-25
WO2001079555A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
AU2001251612A1 (en) Roles of jak/stat family members in tolerance induction
AU2002311794A1 (en) Modular molecular clasps and uses thereof
AU2001264638A1 (en) Functional separation of internal and external controls in network devices
AU2002223028A1 (en) Inhaler
AU2002236700A1 (en) Use of time-stamps and digital signatures
AU2001294884A1 (en) Configurable transformation of electronic documents
AU2001232930A1 (en) Find and dial
AU2003207824A1 (en) K-type polarizer and preparation thereof
AU2001235935A1 (en) Alphanumeric keypad
AU2003212891A1 (en) K-type polarizer and preparation thereof
AU2002357506A1 (en) Acid-containing preparations
AU2001268153A1 (en) Processing of plasmid-containing fluids
AU2002214970A1 (en) The m30 gene family and the utilization thereof
AU2002361550A1 (en) Keratinocyte derived interferon
AU2002340007A1 (en) Hexameric complexes and their preparation
AU2002351095A1 (en) Delivery of digital applications
AU2002363091A1 (en) EE3-protein family and corresponding DNA sequences
AU2001271767A1 (en) The nip3 family of proteins
AU2002214226A1 (en) Fusers and intermediate transfer members
AU2002304792A1 (en) Bacteriophage preparation
AU2002361263A1 (en) Pants-covering and shoe-covering garments
AU2002212283A1 (en) Modular engine family
AU2001260789A1 (en) Wheelchair
AU2002216038A1 (en) Preparation of monofluoroalkenes
AU2002254189A1 (en) Methods of reducing beta-amyloid polypeptides